Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ABEO

Abeona Therapeutics Inc

Apr 28 • 04:00PM ET

5.36

+0.02 0.37 %

Healthcare • Biotechnology • USA • Small • NASD

Peers: BMRN QURE SRPT SGMO BLUE CLGN ADVM FATE VYGR NTLA

| Held by: VTI IWM SURI VXF IWO VTWO ITOT IWC FESM EES

Scroll to Statements

Index	RUT	P/E	5.38	EPS (ttm)	1.00	Insider Own	15.30%	Shs Outstand	55.04M	Perf Week	-0.37%
Market Cap	305.78M	Forward P/E	39.70	EPS next Y	0.14	Insider Trans	-3.00%	Shs Float	48.32M	Perf Month	24.94%
Enterprise Value	139.35M	PEG	9.83	EPS next Q	-0.34	Inst Own	65.64%	Short Float	34.09%	Perf Quarter	4.89%
Income	71.18M	P/S	52.54	EPS this Y	-173.10%	Inst Trans	6.72%	Short Ratio	13.82	Perf Half Y	-2.19%
Sales	5.82M	P/B	1.85	EPS next Y	118.28%	ROA	43.13%	Short Interest	16.47M	Perf YTD	1.71%
Book/sh	2.89	P/C	1.60	EPS next 5Y	4.04%	ROE	70.05%	52W High	7.54 -28.91%	Perf Year	0.19%
Cash/sh	3.36	P/FCF	-	EPS past 3/5Y	- -	ROIC	41.60%	52W Low	4.00 34.00%	Perf 3Y	74.59%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	60.26% -10.26%	Gross Margin	-16.13%	Volatility	4.14% 4.48%	Perf 5Y	-87.24%
Dividend TTM	-	EV/Sales	23.94	EPS Y/Y TTM	175.58%	Oper. Margin	-1536.91%	ATR (14)	0.22	Perf 10Y	-92.29%
Dividend Ex-Date	-	Quick Ratio	6.74	Sales Y/Y TTM	-100.00%	Profit Margin	1223.08%	RSI (14)	57.72	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.93	EPS Q/Q	-82.56%	SMA20	4.10%	Beta	1.32	Target Price	19.57
Payout	0.00%	Debt/Eq	0.16	Sales Q/Q	-	SMA50	7.68%	Rel Volume	0.33	Prev Close	5.34
Employees	226	LT Debt/Eq	0.07	Earnings	Mar 17 BMO	SMA200	-1.21%	Avg Volume	1.19M	Price	5.36
IPO	Sep 19, 1980	Option/Short	Yes / Yes	EPS/Sales Surpr.	-2.27% 12.62%	Trades		Volume	391,262	Change	0.37%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-02-25	Resumed	Oppenheimer	Outperform	$19
Mar-05-25	Initiated	Oppenheimer	Outperform	$16
Jul-03-24	Initiated	H.C. Wainwright	Buy	$15
May-30-24	Initiated	Stifel	Buy	$21
Nov-11-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$4
Sep-18-20	Initiated	B. Riley FBR	Buy	$5
Feb-10-20	Initiated	SVB Leerink	Outperform	$6
Dec-10-19	Resumed	Cantor Fitzgerald	Neutral	$2 → $4
Aug-15-19	Downgrade	Maxim Group	Buy → Hold
Aug-12-19	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$29 → $2
Jul-26-19	Downgrade	Mizuho	Buy → Neutral	$17 → $4
Jun-27-19	Initiated	Mizuho	Buy
Oct-12-18	Initiated	Mizuho	Buy	$17
Jun-05-18	Initiated	Seaport Global Securities	Buy	$29
Nov-08-17	Initiated	SunTrust	Buy	$26
Oct-16-17	Reiterated	H.C. Wainwright	Buy	$20 → $30
Oct-11-17	Reiterated	Cantor Fitzgerald	Overweight	$21 → $34
Oct-10-17	Initiated	Citigroup	Buy	$32
Oct-05-17	Reiterated	Maxim Group	Buy	$17 → $35
Sep-15-17	Initiated	RBC Capital Mkts	Outperform	$23

Show Previous Ratings

Apr-07-26 08:30AM	Abeona Therapeutics Announces Appointment of Keith A. Goldan to its Board of Directors (GlobeNewswire)
Apr-06-26 08:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-02-26 08:30AM	Abeona Therapeutics Announces New Qualified Treatment Center for ZEVASKYN in New York (GlobeNewswire) +5.24%
Mar-20-26 08:30AM	Abeona Therapeutics Inc. Q4 2025 Earnings Call Summary (Moby)
Mar-17-26 03:02PM	Abeona Therapeutics Inc (ABEO) Q4 2025 Earnings Call Highlights: Strong Demand for Zivasskin ... (GuruFocus.com)
07:39AM	Loading…
07:39AM	Abeona Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Abeona Therapeutics Reports Full Year 2025 Financial Results and Corporate Updates (GlobeNewswire)
Mar-09-26 07:30AM	Abeona Therapeutics Provides Business Update Highlighting Building Momentum in ZEVASKYN Commercial Launch (GlobeNewswire) +6.39%
Mar-03-26 07:30AM	Abeona Therapeutics Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference (GlobeNewswire)
Feb-14-26 05:00AM	Netflix Is Casting a Light on a Rare Disease. Pearl Jam's Frontman Is Raising Cash to Cure It. (Barrons.com)
Feb-09-26 10:04AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-31-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-15-25 07:30AM	Abeona Therapeutics Announces Appointment of Mohamad Tabrizi as Chief Business Officer (GlobeNewswire) -5.22%
Dec-11-25 07:30AM	Abeona Therapeutics Announces New Qualified Treatment Center for ZEVASKYN in Texas (GlobeNewswire)
Dec-08-25 07:30AM	Abeona Therapeutics Announces First Patient Treatment with ZEVASKYN Gene Therapy (GlobeNewswire) +5.34%
07:30AM	Loading…
Dec-01-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.72%
Nov-12-25 04:01PM	Abeona Therapeutics Inc (ABEO) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com) +18.47% -8.30%
11:37AM	Here's Why Abeona Therapeutics Popped Higher Today (Motley Fool)
07:40AM	Abeona Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Abeona Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates (GlobeNewswire)
Nov-07-25 07:30AM	Abeona Therapeutics Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation (GlobeNewswire)
Nov-03-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-30-25 10:45AM	Abeona Therapeutics Announces Permanent J-Code for ZEVASKYN (prademagene zamikeracel) (GlobeNewswire)
Oct-20-25 08:30AM	Abeona Therapeutics Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs (GlobeNewswire)
Oct-13-25 07:30AM	Abeona Therapeutics Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program (GlobeNewswire)
Oct-08-25 07:30AM	Abeona Therapeutics and Children's Hospital Colorado Announce Newest Treatment Center for ZEVASKYN Gene Therapy (GlobeNewswire) +5.52%
Oct-01-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-30-25 10:18AM	Krystal Biotech's Heavy Reliance on Vyjuvek: Growth Driver or Risk Factor? (Zacks)
Sep-08-25 08:28AM	Should You Invest in Abeona Therapeutics (ABEO)? (Insider Monkey)
Sep-02-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:30AM	Loading…
Aug-29-25 07:30AM	Abeona Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Aug-14-25 07:38AM	Abeona Therapeutics: Q2 Earnings Snapshot (Associated Press Finance) +10.21%
07:30AM	Abeona Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates (GlobeNewswire)
Aug-11-25 06:19AM	Cell Sheet-based Gene Therapy Market Analysis and Forecast, 2025-2035 \| Abeona Therapeutics, CellSeed, J-TEC, and Holostem Lead with First-in-Class Therapies and Strong Commercialization Strategies (GlobeNewswire)
Aug-01-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-31-25 11:40PM	Abeona Therapeutics, AscellaHealth Partner for Commercialization of ZEVASKYN Gene Therapy (Insider Monkey) -6.32%
Jul-29-25 10:00AM	AscellaHealth HUB Partnership with Abeona Therapeutics® Supports Launch Success of Novel Cell-Based Gene Therapy and Access to Treatment for Rare Disease Patients (GlobeNewswire)
Jul-15-25 07:30AM	ZEVASKYN Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area (GlobeNewswire)
Jul-14-25 07:00AM	Bio-Techne's Simple Western Technology Utilized in Recent FDA Approval of ZEVASKYN Cell-Based Gene Therapy (PR Newswire)
Jul-02-25 07:30AM	Abeona Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million (GlobeNewswire) +5.39%
Jul-01-25 07:30AM	Abeona Therapeutics Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy (GlobeNewswire)
07:15AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-30-25 07:30AM	Abeona Therapeutics added to Membership of U.S. Small-cap Russell 2000 Index and Broad-market Russell 3000 Index (GlobeNewswire)
Jun-24-25 07:30AM	Abeona Therapeutics Announces Publication in The Lancet of Phase 3 VIITAL Study Data in Recessive Dystrophic Epidermolysis Bullosa (GlobeNewswire)
Jun-02-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-30-25 08:46AM	Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-15-25 07:38AM	Abeona Therapeutics: Q1 Earnings Snapshot (Associated Press Finance) +7.42%
07:30AM	Abeona Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates (GlobeNewswire)
May-14-25 08:07AM	UPDATE -- Abeona Therapeutics and Lurie Children's Open First Center for ZEVASKYN Gene Therapy to Treat Wounds in Painful Skin Disorder (GlobeNewswire)
07:30AM	Abeona Therapeutics and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder (GlobeNewswire)
07:30AM	Abeona Therapeutics and Lurie Children's Open First Center for ZEVASKYN Gene Therapy to Treat Wounds in Painful Skin Disorder (GlobeNewswire)
May-13-25 07:21AM	Abeona secures cash runway with $155m priority review voucher sale (Pharmaceutical Technology)
May-12-25 07:30AM	Abeona Therapeutics Enters into Agreement to Sell Priority Review Voucher for $155 Million (GlobeNewswire) +6.26%
04:38AM	Abeona sells speedy drug review voucher for $155M (BioPharma Dive)
May-07-25 04:59PM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.51%
Apr-30-25 07:16AM	FDA approves Abeonas $3.1m cell therapy for rare skin disease (Pharmaceutical Technology) +23.77%
Apr-29-25 03:06PM	Abeona Therapeutics Wins FDA Approval For First-of-Its-Kind Gene Therapy (Benzinga)
06:00AM	U.S. FDA Approves ZEVASKYN (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) (GlobeNewswire)
Apr-27-25 08:30AM	Undercovered Dozen: 3D Systems, Seritage, Topicus, Timken + (Seeking Alpha)
Apr-21-25 10:00AM	Pz-Cel Has Massive Potential For RDEB Patients (Seeking Alpha)
Apr-14-25 07:11AM	Abeona Therapeutics: An Uncertain Pivotal Regulatory Catalyst With Limited Long-Term Upside (Seeking Alpha) +7.61%
Apr-12-25 11:39AM	Abeona Therapeutics: A Buy With Major PDUFA Catalyst On April 29 That Should Send Shares Higher (Seeking Alpha)
Apr-06-25 08:38AM	Krystal Biotech: Some Uncertainty, Some Value (Seeking Alpha)
Apr-01-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.51%
Mar-21-25 03:02AM	Abeona Therapeutics Inc (ABEO) Q4 2024 Earnings Call Highlights: Strategic Advancements and ... (GuruFocus.com)
12:41AM	Q4 2024 Abeona Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-20-25 03:21PM	Abeona Therapeutics targets $2B revenue potential for pz-cel amid U.S. launch preparations (SeekingAlpha)
03:20PM	Abeona Therapeutics Inc. (ABEO) Q4 2024 Earnings Call Transcript (SeekingAlpha)
07:30AM	Abeona Therapeutics Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans (GlobeNewswire)
Mar-04-25 09:00AM	Abeona Therapeutics to Present at the Leerink Partners Global Healthcare Conference (GlobeNewswire)
07:46AM	Abeona Therapeutics announces new employee inducement grants (TipRanks)
Mar-03-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-03-25 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-31-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-02-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-27-24 07:00AM	DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025 (ACCESS Newswire) +6.30%
Nov-15-24 02:06AM	Abeona Therapeutics Inc (ABEO) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Nov-14-24 07:42AM	Abeona Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Abeona Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates (GlobeNewswire)
Nov-12-24 07:30AM	Abeona Therapeutics Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (GlobeNewswire) -5.05%
Nov-04-24 07:30AM	Abeona Therapeutics Announces Participation in November Investor Conferences (GlobeNewswire)
Nov-01-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-29-24 07:30AM	Abeona Therapeutics Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration (GlobeNewswire)
Oct-09-24 06:13PM	Abeona Therapeutics Inc (ABEO) Q2 2024 Earnings Call Highlights: Strong Financial Performance ... (GuruFocus.com)
Oct-01-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-03-24 07:30AM	Abeona Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Sep-02-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-14-24 07:30AM	Abeona Therapeutics Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors (GlobeNewswire)
Aug-13-24 07:30AM	Abeona Therapeutics Announces Favorable Medicare Reimbursement Decisions for Pz-cel (GlobeNewswire)
Aug-12-24 07:37AM	Abeona Therapeutics: Q2 Earnings Snapshot (Associated Press Finance) +11.99%
07:30AM	Abeona Therapeutics Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission (GlobeNewswire)
Aug-01-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-11-24 07:30AM	Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications (GlobeNewswire)
Jul-08-24 07:30AM	Abeona Therapeutics to Present at the Stifel Virtual Cell Therapy Forum (GlobeNewswire) +5.73%
Jun-21-24 03:08AM	Insider Sale: Director Christine Silverstein Sells Shares of Abeona Therapeutics Inc (ABEO) (GuruFocus.com)
Jun-03-24 07:30AM	Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-28-24 07:30AM	Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-16-24 03:01AM	Abeona Therapeutics Inc (ABEO) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances ... (GuruFocus.com)
02:17AM	Q1 2024 Abeona Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-15-24 12:53PM	ABEO Stock Earnings: Abeona Therapeutics Misses EPS for Q1 2024 (InvestorPlace) +12.14%

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Seshadri Vishwas	Chief Executive Officer	Mar 31 '26	Sale	4.38	29,985	131,481	1,430,423	Mar 31 09:03 PM
Seshadri Vishwas	Officer	Mar 31 '26	Proposed Sale	4.38	29,985	131,481		Mar 31 04:42 PM
Vazzano Joseph Walter	Officer	Mar 16 '26	Proposed Sale	4.76	785	3,737		Mar 16 04:31 PM
Vazzano Joseph Walter	Chief Financial Officer	Mar 16 '26	Sale	4.76	785	3,737	567,775	Mar 16 04:29 PM
Silverstein Christine Berni	Director	Feb 02 '26	Proposed Sale	5.09	20,070	102,168		Feb 09 04:01 PM
Silverstein Christine Berni	Director	Feb 02 '26	Sale	5.09	20,070	102,168	137,722	Feb 04 04:30 PM
Wuchterl Donald A.	Director	Feb 02 '26	Sale	5.09	14,814	75,412	167,935	Feb 02 06:59 PM
Crombez Eric	Director	Feb 02 '26	Sale	5.09	16,284	82,895	63,456	Feb 02 06:55 PM
Wuchterl Donald A.	Director	Feb 02 '26	Proposed Sale	5.09	14,814	75,412		Feb 02 04:58 PM
Crombez Eric	Director	Feb 02 '26	Proposed Sale	5.09	16,284	82,886		Feb 02 04:43 PM
Alvino Mark	Director	Feb 02 '26	Proposed Sale	5.09	2,000	10,180		Feb 02 04:40 PM
Alland Leila	Director	Feb 02 '26	Proposed Sale	5.09	18,065	91,962		Feb 02 04:39 PM
Alland Leila	Director	Feb 02 '26	Sale	5.09	18,065	91,962	173,614	Feb 02 04:30 PM
Alvino Mark	Director	Feb 02 '26	Sale	5.09	2,000	10,181	84,065	Feb 02 04:30 PM
Vasanthavada Madhav	Chief Commercial Officer	Jan 22 '26	Sale	5.29	12,610	66,658	318,619	Jan 26 04:35 PM
Vazzano Joseph Walter	Chief Financial Officer	Jan 22 '26	Sale	5.33	18,666	99,507	568,560	Jan 22 08:34 PM
Seshadri Vishwas	Chief Executive Officer	Jan 22 '26	Sale	5.33	69,832	372,267	1,460,408	Jan 22 08:33 PM
O'Malley Brendan M.	SVP, Chief Legal Officer	Jan 22 '26	Sale	5.33	13,578	72,383	451,134	Jan 22 08:33 PM
Vasanthavada Madhav	Officer	Jan 22 '26	Proposed Sale	5.29	12,610	66,658		Jan 22 04:10 PM
Vazzano Joseph Walter	Officer	Jan 22 '26	Proposed Sale	5.33	18,666	99,507		Jan 22 04:09 PM
O'Malley Brendan M.	Officer	Jan 22 '26	Proposed Sale	5.39	13,578	73,233		Jan 22 04:09 PM
Seshadri Vishwas	Officer	Jan 22 '26	Proposed Sale	5.33	69,832	372,267		Jan 22 04:08 PM
Alvino Mark	Director	Jan 21 '26	Sale	5.23	13,500	70,574	48,752	Jan 21 04:30 PM
Alvino Mark	Director	Jan 21 '26	Proposed Sale	5.23	13,500	70,574		Jan 21 04:10 PM
Seshadri Vishwas	Chief Executive Officer	Dec 29 '25	Sale	5.31	25,000	132,740	1,164,818	Dec 29 04:30 PM
Seshadri Vishwas	Officer	Dec 29 '25	Proposed Sale	5.31	25,000	132,695		Dec 29 04:00 PM
Alvino Mark	Director	Nov 13 '25	Sale	4.74	15,000	71,168	62,252	Nov 14 04:30 PM
Alvino Mark	Director	Nov 13 '25	Proposed Sale	4.74	15,000	71,168		Nov 13 04:06 PM
Seshadri Vishwas	Chief Executive Officer	Oct 16 '25	Sale	5.49	249	1,366	1,189,818	Oct 16 04:15 PM
Seshadri Vishwas	Officer	Oct 16 '25	Proposed Sale	5.49	249	1,366		Oct 16 04:09 PM
O'Malley Brendan M.	SVP, Chief Legal Officer	Sep 29 '25	Sale	5.39	9,366	50,516	350,763	Oct 01 04:30 PM
Seshadri Vishwas	Chief Executive Officer	Sep 30 '25	Sale	5.24	25,000	130,930	1,190,067	Oct 01 04:30 PM
Seshadri Vishwas	Chief Executive Officer	Sep 29 '25	Sale	5.39	19,274	103,954	1,215,067	Oct 01 04:30 PM
Vazzano Joseph Walter	Chief Financial Officer	Sep 29 '25	Sale	5.39	9,035	48,730	453,631	Oct 01 04:30 PM
Seshadri Vishwas	Officer	Sep 29 '25	Proposed Sale	5.39	44,274	238,792		Sep 29 04:54 PM
O'Malley Brendan M.	Officer	Sep 29 '25	Proposed Sale	5.39	9,366	50,516		Sep 29 04:44 PM
Vazzano Joseph Walter	Officer	Sep 29 '25	Proposed Sale	5.39	9,366	50,516		Sep 29 04:31 PM
O'Malley Brendan M.	SVP, Chief Legal Officer	Sep 22 '25	Sale	5.43	688	3,736	360,129	Sep 22 07:49 PM
O'Malley Brendan M.	Officer	Sep 22 '25	Proposed Sale	5.86	17,376	101,749		Sep 22 04:23 PM
Crombez Eric	Director	Aug 14 '25	Sale	6.93	4,718	32,683	42,427	Aug 15 04:30 PM
Vazzano Joseph Walter	Chief Financial Officer	Aug 15 '25	Sale	7.36	15,000	110,358	462,666	Aug 15 04:30 PM
Vazzano Joseph Walter	Officer	Aug 15 '25	Proposed Sale	7.36	15,000	110,358		Aug 15 04:15 PM
Vazzano Joseph Walter	Chief Financial Officer	Jul 22 '25	Sale	6.64	1,502	9,975	477,666	Jul 22 04:15 PM
Vazzano Joseph Walter	Officer	Jul 22 '25	Proposed Sale	6.64	1,502	9,975		Jul 22 04:11 PM
Silverstein Christine Berni	Director	Jul 09 '25	Sale	5.86	13,093	76,669	120,479	Jul 10 04:30 PM
Seshadri Vishwas	Chief Executive Officer	Jul 09 '25	Sale	5.86	69,420	406,503	1,234,341	Jul 10 04:30 PM
Vazzano Joseph Walter	Chief Financial Officer	Jul 09 '25	Sale	5.86	25,411	148,799	479,168	Jul 10 04:30 PM
Wuchterl Donald A.	Director	Jul 08 '25	Sale	5.82	5,176	30,147	145,436	Jul 10 04:30 PM
Charles Faith L.	Director	Jul 09 '25	Sale	5.86	10,738	62,879	139,094	Jul 10 04:30 PM
O'Malley Brendan M.	SVP, Chief Legal Officer	Jul 09 '25	Sale	5.86	17,428	102,053	360,817	Jul 10 04:30 PM
Alvino Mark	Director	Jul 09 '25	Sale	5.86	13,093	76,669	77,252	Jul 10 04:30 PM
Vazzano Joseph Walter	Officer	Jul 09 '25	Proposed Sale	5.86	25,335	148,354		Jul 09 04:55 PM
Seshadri Vishwas	Officer	Jul 09 '25	Proposed Sale	5.86	69,215	405,302		Jul 09 04:52 PM
O'Malley Brendan M.	Officer	Jul 09 '25	Proposed Sale	5.86	17,376	101,749		Jul 09 04:48 PM
Charles Faith L.	Director	Jul 09 '25	Proposed Sale	5.86	10,706	62,691		Jul 09 04:45 PM
Silverstein Christine Berni	Director	Jul 09 '25	Proposed Sale	5.86	13,054	76,440		Jul 09 04:40 PM
Alvino Mark	Director	Jul 09 '25	Proposed Sale	5.86	13,054	76,440		Jul 09 04:36 PM
Wuchterl Donald A.	Director	Jul 08 '25	Proposed Sale	5.82	5,176	30,147		Jul 08 04:06 PM
Vazzano Joseph Walter	Chief Financial Officer	Jun 06 '25	Sale	6.76	17,795	120,294	491,246	Jun 06 06:04 PM
Seshadri Vishwas	Chief Executive Officer	Jun 06 '25	Sale	6.76	50,676	342,570	1,303,761	Jun 06 06:00 PM
O'Malley Brendan M.	SVP, General Counsel	Jun 06 '25	Sale	6.76	10,470	70,777	378,245	Jun 06 05:56 PM
Vazzano Joseph Walter	Officer	Jun 06 '25	Proposed Sale	6.76	17,795	120,314		Jun 06 04:13 PM
O'Malley Brendan M.	Director	Jun 06 '25	Proposed Sale	6.76	10,470	70,789		Jun 06 04:12 PM
Seshadri Vishwas	Officer	Jun 06 '25	Proposed Sale	6.76	50,676	342,626		Jun 06 04:11 PM
Alvino Mark	Director	May 27 '25	Sale	6.38	2,000	12,760	90,435	May 27 07:57 PM
Alvino Mark	Director	May 27 '25	Proposed Sale	6.38	2,000	12,762		May 27 04:40 PM
Alvino Mark	Director	May 16 '25	Sale	5.68	8,000	45,440	92,435	May 16 05:23 PM
Alvino Mark	Director	May 16 '25	Proposed Sale	5.68	8,000	45,423		May 16 04:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ABEO

Abeona Therapeutics Inc

Upgrade your Finviz experience